Credit Suisse ~ $FLXN Reports Strong Zilretta Q3 Sales •Patient flow is ~80% of pre-COVID-19 levels •Gross-to-net was ~15% in Q3 •Inventory levels at distributors are consistent with the prior quarter •Flexion Continues to be Excited about the Pipeline Outperform rating $19 PT
  • 1
  • 1
1 Like